Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N03 ANTIEPILEPTICS
N03A ANTIEPILEPTICS
N03AF Carboxamide derivatives
N03AF02 Oxcarbazepine
D00533 Oxcarbazepine (JAN/USP/INN) <US>
USP drug classification [BR:br08302]
Anticonvulsants
Sodium Channel Agents
Oxcarbazepine
D00533 Oxcarbazepine (JAN/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03199 Antiepileptic agent
DG02034 Carboxamide antiepileptic
D00533 Oxcarbazepine
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
D00533 Oxcarbazepine
Metabolizing enzyme inducer
DG02853 CYP3A/CYP3A4 inducer
D00533 Oxcarbazepine
Drug classes [BR:br08332]
Neuropsychiatric agent
DG03199 Antiepileptic agent
D00533 Oxcarbazepine
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Sodium channels
SCN1A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN2A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN3A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN4A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN5A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN8A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN9A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN10A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN11A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D00533
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00533
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00533
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00533
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00533